How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Auteurs : Pinto AC, de Azambuja E, Piccart-Gebhart M
Année : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Auteurs : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Année : 2013
Journal : Breast
Volume : 22 Suppl 2
Pages : S152-5

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Auteurs : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Année : 2013
Journal : J Chemother
Volume : 25(4)
Pages : 239-46

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Auteurs : Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO
Année : 2013
Journal : Breast
Volume : 22(5)
Pages : 606-15

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Auteurs : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Année : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Clinical practice-changing trials: the HERA study paradigm.

Auteurs : Zardavas D, Ades F, de Azambuja E
Année : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pages : 1249-56

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Auteurs : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial.

Auteurs : Azim HA, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart-Gebhart M, de Azambuja E
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(36)
Pages : 4504-11

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Auteurs : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Année : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer

Auteurs : Vanderbeeken MC, de Azambuja E
Année : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 27-30

Technological innovation and healthcare professionals' workloads: an ambiguous relationship.

Auteurs : de Pires DE, Bertoncini JH, Trindade Lde L, Matos E, de Azambuja E, Borges AM
Année : 2012
Journal : Rev Gaucha Enferm
Volume : 33(1)
Pages : 157-68

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Auteurs : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Année : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pages : vii155-66

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Auteurs : Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, de Azambuja E, Hainaut P, + collaborators (among others :, Larsimont D, Piccart-Gebhart M, Olivier M
Année : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : R70

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer.

Auteurs : Pugliano L, de Azambuja E
Année : 2012
Journal : Onkologie
Volume : 35(9)
Pages : 476-8

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Auteurs : Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M
Année : 2012
Journal : J Oncol
Volume : 2012
Pages : 417673

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Année : 2012
Journal : Lancet
Volume : 379(9816)
Pages : 633-40

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

Auteurs : Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M
Année : 2012
Journal : Breast Cancer Res. Treat.
Volume : 133(1)
Pages : 387-91

Dissecting the heterogeneity of triple-negative breast cancer.

Auteurs : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Année : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pages : 1879-87

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Auteurs : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Année : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : 209

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Auteurs : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22